466 related articles for article (PubMed ID: 19286303)
1. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
Aus G
Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
[No Abstract] [Full Text] [Related]
2. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
Albertson PC
Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
[No Abstract] [Full Text] [Related]
3. Active surveillance for prostate cancer: has the time finally come?
Aragon-Ching JB
J Clin Oncol; 2010 Jun; 28(16):e265-6; author reply e267. PubMed ID: 20406916
[No Abstract] [Full Text] [Related]
4. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
5. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
Ercole B; Marietti SR; Fine J; Albertsen PC
J Urol; 2008 Oct; 180(4):1336-9; discussion 1340-1. PubMed ID: 18707696
[TBL] [Abstract][Full Text] [Related]
6. Insignificant prostate cancer and active surveillance: from definition to clinical implications.
Bastian PJ; Carter BH; Bjartell A; Seitz M; Stanislaus P; Montorsi F; Stief CG; Schröder F
Eur Urol; 2009 Jun; 55(6):1321-30. PubMed ID: 19286302
[TBL] [Abstract][Full Text] [Related]
7. The prostate specific antigen. Its use as a tumor marker for prostate cancer.
Kantoff PW; Talcott JA
Hematol Oncol Clin North Am; 1994 Jun; 8(3):555-72. PubMed ID: 8707772
[TBL] [Abstract][Full Text] [Related]
8. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
Joniau S
Eur Urol; 2008 Feb; 53(2):362. PubMed ID: 17611018
[No Abstract] [Full Text] [Related]
9. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
Scattoni V
Eur Urol; 2008 Feb; 53(2):361. PubMed ID: 17611014
[No Abstract] [Full Text] [Related]
10. Active surveillance in young patients with prostate cancer: the unanswered question.
Campodonico F; Maffezzini M
J Clin Oncol; 2010 May; 28(13):e211; author reply e212. PubMed ID: 20368544
[No Abstract] [Full Text] [Related]
11. Treatment of stage A1 prostate cancer: the case for treatment.
Bahnson RR
Semin Urol; 1993 May; 11(2):54-7. PubMed ID: 7689739
[No Abstract] [Full Text] [Related]
12. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Gallina A
Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
[No Abstract] [Full Text] [Related]
13. Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Yossepowitch O
Eur Urol; 2010 Apr; 57(4):639-40. PubMed ID: 19299071
[No Abstract] [Full Text] [Related]
14. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
Thompson IM; Ankerst DP; Etzioni R; Wang T
J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
[No Abstract] [Full Text] [Related]
15. [PSA doubling times of prostate carcinoma managed with watchful observation alone].
Dunst J
Strahlenther Onkol; 2001 Dec; 177(12):684-5. PubMed ID: 11789411
[No Abstract] [Full Text] [Related]
16. Prostate-specific antigen dynamics and prostate cancer diagnosis.
Bartoletti R
Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
[No Abstract] [Full Text] [Related]
17. Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?
Klotz L
Curr Urol Rep; 2007 Sep; 8(5):341-4. PubMed ID: 17880830
[No Abstract] [Full Text] [Related]
18. Screening for prostate cancer remains controversial.
Stark JR; Mucci L; Rothman KJ; Adami HO
BMJ; 2009 Sep; 339():b3601. PubMed ID: 19778971
[No Abstract] [Full Text] [Related]
19. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance.
Porten SP; Whitson JM; Cowan JE; Cooperberg MR; Shinohara K; Perez N; Greene KL; Meng MV; Carroll PR
J Clin Oncol; 2011 Jul; 29(20):2795-800. PubMed ID: 21632511
[TBL] [Abstract][Full Text] [Related]
20. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
[Next] [New Search]
